Arbutus Biopharma/$ABUS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Arbutus Biopharma
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
Ticker
$ABUS
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
44
ISIN
CA03879J1003
Website
ABUS Metrics
BasicAdvanced
$665M
-
-$0.41
1.50
-
Price and volume
Market cap
$665M
Beta
1.5
52-week high
$3.73
52-week low
$2.71
Average daily volume
709K
Financial strength
Current ratio
6.011
Quick ratio
6.011
Long term debt to equity
6.361
Total debt to equity
7.072
Interest coverage (TTM)
-558.17%
Profitability
EBITDA (TTM)
-66.183
Gross margin (TTM)
-643.29%
Net profit margin (TTM)
-1,195.86%
Operating margin (TTM)
-1,054.79%
Revenue per employee (TTM)
$150,000
Management effectiveness
Return on assets (TTM)
-31.58%
Return on equity (TTM)
-79.02%
Valuation
Price to revenue (TTM)
102.632
Price to book
8.39
Price to tangible book (TTM)
8.39
Price to free cash flow (TTM)
-11.114
Free cash flow yield (TTM)
-9.00%
Free cash flow per share (TTM)
-31.22%
Growth
Revenue change (TTM)
-50.69%
Earnings per share change (TTM)
-7.37%
3-year revenue growth (CAGR)
-33.17%
10-year revenue growth (CAGR)
-8.29%
3-year earnings per share growth (CAGR)
-16.68%
10-year earnings per share growth (CAGR)
-11.35%
Bulls say / Bears say
Arbutus Biopharma's imdusiran achieved a 50% functional cure rate in chronic hepatitis B patients with baseline HBsAg levels below 1000 IU/mL in the IM-PROVE I Phase 2a trial, indicating strong potential for future treatments. (arbutusbio.com)
Chardan Capital raised its price target for Arbutus Biopharma to $5 from $4.50, citing promising data from the IM-PROVE I and II trials, suggesting confidence in the company's clinical progress. (nasdaq.com)
Arbutus Biopharma reported a net loss of $69.9 million for 2024, an improvement from the $72.8 million loss in 2023, reflecting effective cost management and operational efficiency. (biospace.com)
StockNews.com downgraded Arbutus Biopharma to a 'Sell' rating, indicating concerns about the company's future performance. (defenseworld.net)
Arbutus Biopharma's revenue decreased to $6.2 million in 2024 from $18.1 million in 2023, primarily due to reduced license revenue and lower sales of ONPATTRO, raising concerns about the company's revenue streams. (biospace.com)
Roivant Sciences replaced Arbutus Biopharma's entire board of directors in February 2025, which may indicate internal challenges and potential instability within the company's leadership. (tipranks.com)
Data summarised monthly by Lightyear AI. Last updated on 4 Jun 2025.
ABUS News
AllArticlesVideos
Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewsWire·1 month ago
Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025
GlobeNewsWire·1 month ago
Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Arbutus Biopharma stock?
Arbutus Biopharma (ABUS) has a market cap of $665M as of June 20, 2025.
What is the P/E ratio for Arbutus Biopharma stock?
The price to earnings (P/E) ratio for Arbutus Biopharma (ABUS) stock is 0 as of June 20, 2025.
Does Arbutus Biopharma stock pay dividends?
No, Arbutus Biopharma (ABUS) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Arbutus Biopharma dividend payment date?
Arbutus Biopharma (ABUS) stock does not pay dividends to its shareholders.
What is the beta indicator for Arbutus Biopharma?
Arbutus Biopharma (ABUS) has a beta rating of 1.5. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.